Over 61,383 mpox cases and 296 deaths across 32 African countries since early 2024, but hope’s rising with a major clinical trial gaining steam to deliver real treatments! Africa CDC dropped the stats Saturday in Abuja, spotlighting the MOSA study—a double-blind trial testing therapies in hard-hit nations like DRC.
Launched in 2024 with EU and Africa CDC funding, MOSA just scored fresh backing from Emergent BioSolutions and PANTHER after a safety review greenlit expansion to Uganda; no red flags in the first 50 patients.
DG Dr. Jean Kaseya hailed it as key for Africa-led responses to Clade I/II outbreaks, while Emergent Dr. Simon Lowry pledged more collab: no dedicated antiviral exists yet, making this pivotal for future-proofing the continent!
Leave a comment